<DOC>
	<DOC>NCT02556775</DOC>
	<brief_summary>The purpose of this registry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), regarding the course and outcome of pregnancy in women ever treated with HYQVIA. Development of the fetus/infant at birth and for the first 2 years will also be followed.</brief_summary>
	<brief_title>Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia (Immune Globulin (Human) 10% With rHuPH20)</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>For the expectant mother only: Participant became pregnant during or after treatment with HYQVIA Participant/Participant's legally authorized representative is willing to sign an informed consent form (ICF) There are no applicable Exclusion Criteria</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>